MedPath

Effect of alternate day treatment with teneligliptin in type 2 diabetes mellitus patients.

Phase 4
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2024/06/068564
Lead Sponsor
ONE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Patients with T2DM visiting Medicine / Endocrinology OPD/Ward who are taking metformin =1000 mg for a duration of 3 months or more.

2) Age:18- 59 years.

3) HbA1c 7-9 %

Exclusion Criteria

1) Type 1 Diabetes patients.

2) Patients taking metformin for less than 3 months duration.

3) Patients with known allergy to study drugs.

4) Pregnant and lactating women.

5)Patients with uncontrolled cardiovascular disorders.

6) Patients with severe life-threatening diseases.

7) Patients having renal dysfunction (serum creatinine 1.5 times more than the upper normal limit range).

8) Cases with hepatic dysfunction (SGOT and/ or SGPT levels 3-fold more than upper limit range).

9) Patients who have recent history of diabetic ketoacidosis.

10) Patients who are not willing / unable to give written informed consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath